| Kevin Saiki, MD | |
|
1301 Punchbowl St, Honolulu, HI 96813-2499 | |
| (808) 691-1000 | |
| Not Available |
| Full Name | Kevin Saiki |
|---|---|
| Gender | Male |
| Speciality | Obstetrics & Gynecology - Maternal & Fetal Medicine |
| Location | 1301 Punchbowl St, Honolulu, Hawaii |
| Accepts Medicare Assignments | Medicare enrolled and may accept medicare through third-party reassignment. May prescribe medicare part D drugs. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1215391990 | NPI | - | NPPES |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 207VM0101X | Obstetrics & Gynecology - Maternal & Fetal Medicine | MD-21023 (Hawaii) | Primary |
| Entity Name | Kapiolani Medical Center For Women & Children |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1548215692 PECOS PAC ID: 9830097914 Enrollment ID: O20031229000149 |
News Archive
Endoscopic sleeve gastroplasty, a relatively new, minimally invasive weight-loss procedure, resulted in significant total body weight loss in the first long-term study to follow patients' progress over five years, according to research presented at Digestive Disease Week 2019.
Halozyme Therapeutics, Inc. today announced that the primary endpoint of non-inferiority of A1C levels at six months was met for the CONSISTENT 1 trial. The trial is evaluating Hylenex® recombinant and a new formulation of Hylenex currently under U.S Food and Drug Administration (FDA) review, when used as pretreatment of the insulin infusion site in patients with type 1 diabetes receiving continuous subcutaneous insulin infusion (CSII) in comparison to no pre-treatment.
ValenTx, Inc., announced today the closing of a $22 million Series B Preferred Stock financing. The round was led by SV Life Sciences and joined by Covidien Ventures, as well as all the Company's existing venture capital investors: Sapient Capital, EDF Ventures, Kaiser Permanente Ventures, Affinity Capital Partners, and TGap Ventures.
Through a detailed study of leukaemia cells from more than 200 children, a research group at Lund University in Sweden has discovered two new types of childhood leukaemia.
Porter Adventist Hospital has received certification as an Advanced Primary Stroke Center by The Joint Commission on Accreditation of Healthcare Organizations. The Certificate of Distinction, received in December after an on-site review in the fall, recognizes the exceptional efforts the Porter Stroke Program has made with a cohesive, multidisciplinary approach to foster better outcomes for stroke patients.
› Verified 4 days ago
| Entity Name | The Queens Medical Center |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1487693586 PECOS PAC ID: 3476454067 Enrollment ID: O20040116000366 |
News Archive
Endoscopic sleeve gastroplasty, a relatively new, minimally invasive weight-loss procedure, resulted in significant total body weight loss in the first long-term study to follow patients' progress over five years, according to research presented at Digestive Disease Week 2019.
Halozyme Therapeutics, Inc. today announced that the primary endpoint of non-inferiority of A1C levels at six months was met for the CONSISTENT 1 trial. The trial is evaluating Hylenex® recombinant and a new formulation of Hylenex currently under U.S Food and Drug Administration (FDA) review, when used as pretreatment of the insulin infusion site in patients with type 1 diabetes receiving continuous subcutaneous insulin infusion (CSII) in comparison to no pre-treatment.
ValenTx, Inc., announced today the closing of a $22 million Series B Preferred Stock financing. The round was led by SV Life Sciences and joined by Covidien Ventures, as well as all the Company's existing venture capital investors: Sapient Capital, EDF Ventures, Kaiser Permanente Ventures, Affinity Capital Partners, and TGap Ventures.
Through a detailed study of leukaemia cells from more than 200 children, a research group at Lund University in Sweden has discovered two new types of childhood leukaemia.
Porter Adventist Hospital has received certification as an Advanced Primary Stroke Center by The Joint Commission on Accreditation of Healthcare Organizations. The Certificate of Distinction, received in December after an on-site review in the fall, recognizes the exceptional efforts the Porter Stroke Program has made with a cohesive, multidisciplinary approach to foster better outcomes for stroke patients.
› Verified 4 days ago
| Entity Name | Queens University Medical Group |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1891441382 PECOS PAC ID: 2466831557 Enrollment ID: O20220621000534 |
News Archive
Endoscopic sleeve gastroplasty, a relatively new, minimally invasive weight-loss procedure, resulted in significant total body weight loss in the first long-term study to follow patients' progress over five years, according to research presented at Digestive Disease Week 2019.
Halozyme Therapeutics, Inc. today announced that the primary endpoint of non-inferiority of A1C levels at six months was met for the CONSISTENT 1 trial. The trial is evaluating Hylenex® recombinant and a new formulation of Hylenex currently under U.S Food and Drug Administration (FDA) review, when used as pretreatment of the insulin infusion site in patients with type 1 diabetes receiving continuous subcutaneous insulin infusion (CSII) in comparison to no pre-treatment.
ValenTx, Inc., announced today the closing of a $22 million Series B Preferred Stock financing. The round was led by SV Life Sciences and joined by Covidien Ventures, as well as all the Company's existing venture capital investors: Sapient Capital, EDF Ventures, Kaiser Permanente Ventures, Affinity Capital Partners, and TGap Ventures.
Through a detailed study of leukaemia cells from more than 200 children, a research group at Lund University in Sweden has discovered two new types of childhood leukaemia.
Porter Adventist Hospital has received certification as an Advanced Primary Stroke Center by The Joint Commission on Accreditation of Healthcare Organizations. The Certificate of Distinction, received in December after an on-site review in the fall, recognizes the exceptional efforts the Porter Stroke Program has made with a cohesive, multidisciplinary approach to foster better outcomes for stroke patients.
› Verified 4 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Kevin Saiki, MD 1301 Punchbowl St, Honolulu, HI 96813-2499 Ph: (808) 691-1000 | Kevin Saiki, MD 1301 Punchbowl St, Honolulu, HI 96813-2499 Ph: (808) 691-1000 |
News Archive
Endoscopic sleeve gastroplasty, a relatively new, minimally invasive weight-loss procedure, resulted in significant total body weight loss in the first long-term study to follow patients' progress over five years, according to research presented at Digestive Disease Week 2019.
Halozyme Therapeutics, Inc. today announced that the primary endpoint of non-inferiority of A1C levels at six months was met for the CONSISTENT 1 trial. The trial is evaluating Hylenex® recombinant and a new formulation of Hylenex currently under U.S Food and Drug Administration (FDA) review, when used as pretreatment of the insulin infusion site in patients with type 1 diabetes receiving continuous subcutaneous insulin infusion (CSII) in comparison to no pre-treatment.
ValenTx, Inc., announced today the closing of a $22 million Series B Preferred Stock financing. The round was led by SV Life Sciences and joined by Covidien Ventures, as well as all the Company's existing venture capital investors: Sapient Capital, EDF Ventures, Kaiser Permanente Ventures, Affinity Capital Partners, and TGap Ventures.
Through a detailed study of leukaemia cells from more than 200 children, a research group at Lund University in Sweden has discovered two new types of childhood leukaemia.
Porter Adventist Hospital has received certification as an Advanced Primary Stroke Center by The Joint Commission on Accreditation of Healthcare Organizations. The Certificate of Distinction, received in December after an on-site review in the fall, recognizes the exceptional efforts the Porter Stroke Program has made with a cohesive, multidisciplinary approach to foster better outcomes for stroke patients.
› Verified 4 days ago
Deborah A. Buccigrossi, MD Obstetrics & Gynecology Medicare: Not Enrolled in Medicare Practice Location: 1010 Pensacola St, Honolulu, HI 96814 Phone: 808-432-2000 | |
Cheryl Lynn Tanguilig Rudy, M.D. Obstetrics & Gynecology Medicare: Accepting Medicare Assignments Practice Location: 1319 Punahou St, Suite 760, Honolulu, HI 96826 Phone: 808-947-5606 Fax: 808-947-5805 | |
Dr. Gwendolyn Patricia Chung, M.D. Obstetrics & Gynecology Medicare: Accepting Medicare Assignments Practice Location: 1441 Kapiolani Boulevard, Suite 1810, Honolulu, HI 96814 Phone: 808-949-5308 Fax: 808-943-0963 | |
Dr. Hong-ru Chen, MD Obstetrics & Gynecology Medicare: Accepting Medicare Assignments Practice Location: 1319 Punahou St, Ste 515, Honolulu, HI 96826 Phone: 808-951-6006 Fax: 818-875-0005 | |
Dr. Benakar Fonseca Batista, M.D. Obstetrics & Gynecology Medicare: Accepting Medicare Assignments Practice Location: 1319 Punahou St, Honolulu, HI 96826 Phone: 808-983-6931 | |
Asia Ayabe, MD Obstetrics & Gynecology Medicare: Not Enrolled in Medicare Practice Location: 3288 Moanalua Rd, Honolulu, HI 96819 Phone: 808-983-6000 | |
Rosemarie S. W. Chang, M.D. Obstetrics & Gynecology Medicare: Not Enrolled in Medicare Practice Location: 1319 Punahou St Ste 515, Honolulu, HI 96826 Phone: 808-951-6006 Fax: 808-943-2634 |